Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
AssigneeAstraZeneca AB
InventorsJohan Olof Broddefalk, Hans Fredrik Emtenâs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
Life of this patent
Estimating the term…
Abstract
The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
Claims15
A method of treating respiratory inflammatory disease and complications associated with respiratory inflammatory disease, comprising administering to a patient in need thereof an effective amount of a compound of formula (IV):
- or a pharmaceutically acceptable salt thereof, wherein:
- X1 is CH or CCH3;
- R2 is —H or —F;
- R4 is —H or —CH3;
- and
- R8 is —H or CH3.
A method of treating asthma, comprising administering to a patient in need thereof (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-α]pyrazin-3-cyclohexanecarboxamide.
Dependencies are inferred from the claim text.